Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on November 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q3 2021, ending September 30, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Imara Inc. (Nasdaq: IMRA) will host a conference call and webcast on November 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q3 2021, ending September 30, 2021.
The event will cover recent business highlights and can be accessed by calling 1 (833) 519-1307 (U.S.) or +1 (914) 800-3873 (international) with conference ID 1235955. The live webcast will be available on the company's website, with a replay archived afterward.
Imara focuses on developing therapeutics for rare genetic disorders related to hemoglobin, including sickle cell disease and beta-thalassemia.
Positive
- Upcoming conference call to discuss financial results, potentially providing clarity on operational performance.
- Continued development of therapeutics like tovinontrine (IMR-687) and IMR-261, targeting serious diseases.
Negative
- None.
Details
News Market Reaction – IMRA
The recorded move for IMRA in the trading session of this news was -2.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and review recent business highlights.
A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 1235955. A replay of the webcast will be archived on the Imara website following the presentation.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment currently in clinical development for sickle cell disease and beta-thalassemia and preclinical development for HFpEF. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2 (Nrf2). For more information, please visit www.imaratx.com.
Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com
Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.